Posted by Dr. Stan Guberman on 4/4/2013
Latest Nutritional News
The Sarasota, Florida based Diagnostic Center for Disease(TM) in conjunction with PanAm HIFU, LLC, released data today showing a 95% cure rate with HIFU (High Intensity Focused Ultrasound) in more than 200 patients at more than 7 years post treatment. This group of patients had biopsy proven prostate cancer in conjunction with a 3.0 Tesla Magnetic Resonance Imaging Spectroscopy scan (MRI-S). Ronald E. Wheeler, M.D. (Medical Director) attributes the results to excellence in imaging, excellence in application of technology as well as excellence in patient selection. While MRI-S continues to be evaluated in a head to head comparison to random prostate biopsies, it appears the MRI-S scan is the missing piece of the diagnostic puzzle allowing for a dramatic improvement in treatment results. Approximately 700,000 American men receive a negative prostate biopsy result; however approximately 25% of these results are false-negative. Under the current standard of care, prostate biopsy procedures collect 10-12 needle biopsy cores on average, effectively sampling less than 1% of a man's prostate. This approach leaves men at risk for a hidden cancer, leading to a high rate of repeat biopsies, often on cancer-free men, which hinders or delays the application of a procedure with this high rate of cure.
Specifically, the MRI-S scan allows for an enhancement of various diagnostic discrimination factors including: evidence of extracapsular extension (ECE), dominance of cancer in a side to side assessment, true density of tissue based on a diffusion weighted image sequence (DWI), dynamic contrast enhancement (DCE) and spectroscopy (if assessable). Once the patient assessment has taken place, a qualified HIFU treating expert can expect to experience predictably better results than those achieved without the MRI-S scan. Dr. Wheeler goes on to say that current worldwide data with HIFU (regardless of technology utilized) supports a cure rate of approximately 78-80%. Our data is a seminal study that enables prostate cancer patients the opportunity to improve their choice of one therapy versus another.
Interested patients are asked to call the clinic directly for more information at: 941-957-0007, or visit www.mrisusa.com or www.panamhifu.com.